Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given an average recommendation of “Buy” by the eight analysts that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $19.29.

A number of research analysts have weighed in on REPL shares. Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright boosted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th.

Replimune Group Price Performance

REPL opened at $13.98 on Thursday. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -4.55 and a beta of 1.30. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a 50-day moving average price of $12.68 and a 200-day moving average price of $11.87.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts expect that Replimune Group will post -2.97 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC boosted its holdings in Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after acquiring an additional 1,655 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd boosted its position in Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Replimune Group during the 4th quarter valued at $117,000. Finally, Quantinno Capital Management LP purchased a new stake in Replimune Group during the 4th quarter valued at $127,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.